Literature DB >> 9888819

A new model system for lipid interactions in stratum corneum vesicles: effects of lipid composition, calcium, and pH.

R M Hatfield1, L W Fung.   

Abstract

We prepared large unilamellar vesicles (LUVs) with three different stratum corneum lipid compositions: constant amounts of ceramides (55 wt %) and fatty acids (15%) with varying amounts of cholesterol sulfate (0-15%) and cholesterol (15-30%). One of the compositions served as a model for normal stratum corneum, while the second one served as a model for recessive X-linked ichthyosis stratum corneum. The third composition consisted of no cholesterol sulfate. Intervesicle lipid interactions in these LUVs were monitored by fluorescence methods for content leakage, and contents mixing at pH 9, in the absence and presence of Ca2+, and at pH 6. Since the content leakage and contents mixing assays were originally developed for phospholipid vesicles, we characterized the probe binding and the probe quenching properties for stratum corneum LUV systems, and modified the assays slightly accordingly. The time-dependent fluorescence intensity changes in the probe-containing LUVs at pH 9 and 6 and in response to the addition of calcium were monitored. Our results demonstrated that all three types of LUVs were relatively stable at pH 9. Addition of Ca2+ or decreasing the pH to 6 activated intervesicle lipid mixing followed by vesicle fusion and lysis. We found that the LUVs with no cholesterol sulfate and 30% cholesterol exhibited a more extensive Ca2+- or low-pH-activated intervesicle lipid interaction than LUVs with either 5% cholesterol sulfate and 25% cholesterol or 15% cholesterol sulfate and 15% cholesterol. These results suggest that fusogenic agents such as Ca2+ and H+ act to neutralize the fatty acids in the lipid bilayer of stratum corneum vesicles. The inclusion of 5-15% cholesterol sulfate helps to prevent the collapse of fused vesicles into other structures.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888819     DOI: 10.1021/bi981421k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Cholesterol sulfate and Ca(2+) modulate the mixing properties of lipids in stratum corneum model mixtures.

Authors:  Marjolaine Arseneault; Michel Lafleur
Journal:  Biophys J       Date:  2006-10-06       Impact factor: 4.033

2.  Abnormal barrier function in the pathogenesis of ichthyosis: therapeutic implications for lipid metabolic disorders.

Authors:  Peter M Elias; Mary L Williams; Kenneth R Feingold
Journal:  Clin Dermatol       Date:  2012 May-Jun       Impact factor: 3.541

3.  Stratum corneum lipid liposomes for investigating skin penetration enhancer effects.

Authors:  Mónika Bakonyi; Attila Gácsi; Szilvia Berkó; Anita Kovács; Erzsébet Csányi
Journal:  RSC Adv       Date:  2018-08-02       Impact factor: 4.036

Review 4.  Role of cholesterol sulfate in epidermal structure and function: lessons from X-linked ichthyosis.

Authors:  Peter M Elias; Mary L Williams; Eung-Ho Choi; Kenneth R Feingold
Journal:  Biochim Biophys Acta       Date:  2013-11-27

Review 5.  Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism.

Authors:  Peter M Elias; Mary L Williams; Walter M Holleran; Yan J Jiang; Matthias Schmuth
Journal:  J Lipid Res       Date:  2008-02-02       Impact factor: 5.922

6.  Mutations in SULT2B1 Cause Autosomal-Recessive Congenital Ichthyosis in Humans.

Authors:  Lisa Heinz; Gwang-Jin Kim; Slaheddine Marrakchi; Julie Christiansen; Hamida Turki; Marc-Alexander Rauschendorf; Mark Lathrop; Ingrid Hausser; Andreas D Zimmer; Judith Fischer
Journal:  Am J Hum Genet       Date:  2017-06-01       Impact factor: 11.025

7.  High-Throughput Screening of Potential Skin Penetration-Enhancers Using Stratum Corneum Lipid Liposomes: Preliminary Evaluation for Different Concentrations of Ethanol.

Authors:  Pajaree Sakdiset; Yuki Kitao; Hiroaki Todo; Kenji Sugibayashi
Journal:  J Pharm (Cairo)       Date:  2017-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.